Redefining the Future of Cardiovascular Health
21M
lives claimed
worldwide every year
130M+
people live with this
disease in the U.S. alone
The two most important drivers
of cardiovascular disease are
HIGH BLOOD
PRESSURE
(hypertension)
ELEVATED
CHOLESTEROL
(particularly high levels of low-density lipoprotein cholesterol, or LDL-C, which lead to arterial plaque formation and growth).
Current medical practice does not adequately address the health burden of cardiovascular disease. Physicians usually treat high blood pressure and high cholesterol only after substantial cumulative undetected exposure. But by this time, significant injury to arterial walls has already occurred; inflammation and structural damage from blood pressure and the risk of future cardiovascular-related events is already markedly elevated.
Corsera Health's innovative and proactive approach, intervening before the damage has been done, has the potential to dramatically reduce morbidity and mortality.
The focus of coronary artery disease needs to shift
from the late stages of the
disease, coronary artery obstruction and
resultant ischemia and infarction, towards
strategies aimed at early prevention,
regression and cure of atherosclerosis.
The Lancet Commission on rethinking coronary artery disease:
moving forward from ischaemia to atheroma, April 2025
CORSERA HEALTH:
THE POWER TO PREDICT AND PREVENT
Effective prevention must target multiple risk factors while ensuring long-term persistence and accessibility. Corsera Health is developing a preventive RNAi medicine designed to reduce the production of validated disease drivers. Intended for once-annual administration, this medicine aims to provide population-scale reach, ease of use, and pricing that enables broad access.
Initial Cardiovascular Health Assessment
John Doe
40 years oldLifetime Risk
High Blood Pressure
High Cholesterol
Cardiovascular Disease Risk
Once-Annual Preventive RNAi Medicine
Quantify Benefit of Early Intervention
John Doe
40-90+ years oldResidual Lifetime Risk
High Blood Pressure
High Cholesterol
Cardiovascular Disease Risk
Aims to provide population-scale reach, ease of use, and pricing that enables broad access